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During the past decade, atrial fibrillation (AF) and atrial
flutter (AFL) together have emerged as the most common
cardiac arrhythmias encountered in clinical practice and are
responsible for considerable morbidity and mortality. At-
tempts at reducing these complications have focused on con-
trolling ventricular rate with agents that impede conduction
over the atrioventricular node combined with anticoagulation
to prevent strokes or, alternatively, on the restoration and
maintenance of sinus rhythm (1). The relative merits of the two
approaches remain unclear. However, their impact with re-
spect to the incidence of strokes and heart failure, alteration in
exercise capacity and overall quality as well as the quantity of
life is being examined in several ongoing controlled clinical
trials. Despite the lack of conclusive data, it is widely believed
that antifibrillatory compounds that have no adverse effect on
mortality, but with the propensity to maintain sinus rhythm
over long periods of time in patients prone to AF and AFL,
would hold much clinical appeal. In this context, therefore, the
development of compounds that produced an isolated or
selective prolongation of myocardial repolarization has been of
particular therapeutic interest (2). It is known that in patients
susceptible to AF, the atrial refractory period is significantly
shortened. Furthermore, it has been reported that in patients
with AF converted to sinus rhythm by direct current (DC)
cardioversion, relapses are more likely to occur in those with
the shorter atrial refractory period (2). These observations are
in line with a large body of data from experimental models of
AF in which the reentrant nature of the arrhythmia is now
reasonably well established. In electrophysiologic terms, it
follows that compounds that consistently and predictably
lengthen repolarization in atrial muscle by whatever ionic
mechanisms are likely not only to terminate AF after short-
term administration, but they may also reduce the possibility of
recurrence during long-term therapy as a result of sustained
lengthening of the atrial refractory period.
During the past three decades, transthoracic DC shocks
have been used to restore sinus rhythm in patients with AF and
AFL; the reported success rates for conversion have been
between 75% and 95% (3). With such a high conversion rate,
it is not surprising that pharmacologic conversion for termi-
nating AF and AFL has not been widely favored nor system-
atically investigated. Uncontrolled or poorly controlled obser-
vations nevertheless have revealed much lower conversion
rates with oral or intravenous formulations of conventional
antiarrhythmic agents, such as quinidine, procainamide, and
disopyramide or beta-adrenergic blocking agents, and stan-
dardized regimens have not been developed. However, in
Europe, intravenous sotalol, amiodarone, propafenone and
flecainide have been used for conversion. In contrast, it has
always been recognized that the availability of an effective and
safe pharmacologic conversion of AF and AFL is likely to have
significant advantages over transthoracic DC cardioversion in
the manner offered by intravenous calcium channel blocking
agents and adenosine for reentrant paroxysmal supraventricu-
lar tachycardias. Pharmacologic conversion obviates the neces-
sity for general anesthesia and is therefore likely to be less
costly, an issue that can no longer be ignored.
For these reasons, the report by Falk et al. (4) in this issue
of the Journal on the rate of conversion of AF and AFL
induced by intravenous dofetilide in patients with these ar-
rhythmias once again draws attention to the possibility of a
systematic approach to the pharmacologic conversion of AF
and AFL. Dofetilide selectively blocks the rapid component of
the delayed rectifier potassium current (IKr) in the heart, and
it has been characterized as a pure class III agent. The
definition of its potential role in the acute conversion of AF
followed logically in the wake of the knowledge that the key
determinant of AF is the shortening of the atrial refractory
period (2).
Study with dofetilide. In a double-blind, placebo-con-
trolled study in 91 patients (75 with AF, 16 with AFL), the
conversion rate was 31% in patients with AF given 8 mg/kg
body weight of dofetilide intravenously and 12.5% in those
given 4 mg/kg; there were no conversions for placebo. For
AFL, the conversion rate was 54% (one for the lower dose, five
for the higher dose; again, there were no conversions for
placebo). There were two cases of torsade de pointes as a
proarrhythmic reaction in 2 of 62 patients exposed to dofetil-
ide. What may be inferred from these data? It must be
appreciated that this is a relatively small study; it is not
balanced with respect to placebo, and it defines only the
lowermost drug dose for conversion. It remains unclear
whether a dose.8 mg/kg might have produced a higher rate of
conversion in the case of AF. Conversely, a lower rate of
conversion might be expected if tested in patients whose AF
had been present for periods .6 months. It also leaves open
the possibility that at higher doses, a greater incidence of
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proarrhythmic reactions might be encountered. Clearly, more
data are needed to permit the delineation of the potential role
of dofetilide for the acute conversion of AF and AFL in the
clinic. Nevertheless, two conclusions can be reached: 1) The
rate of conversion of the two atrial arrhythmias by intravenous
dofetilide is significantly higher than that by placebo. Undoubt-
edly, this finding in the human atria clearly vindicates the
hypothesis promulgated .25 years ago that isolated prolonga-
tion of repolarization was an antiarrhythmic mechanism (5). 2)
Although the number of patients examined for both AF and
AFL was small, the overall percentage conversion rates for
dofetilide found by Falk et al. (4) are not strikingly dissimilar
to those reported for ibutilide (another pure class III agent
that has recently been approved by the Food and Drug
Administration for the acute conversion of AF and AFL) in
two larger and more rigorously conducted studies published
recently (6,7).
Studies with ibutilide. In the first of these studies reported
in a previous issue of the Journal, Ellenbogen et al. (6)
examined the safety and efficacy of intravenous ibutilide in 200
patients with AF and AFL between 3 h and 90 days in duration
and structural heart disease in 70%, who were randomized in
equal numbers to receive placebo and four different doses of
the drug (0.005, 0.010, 0.015 and 0.025 mg/kg given over
10 min). The placebo conversion rate was 3%, and those for
the four ascending doses of ibutilide were 12%, 33%, 45% and
46%, respectively. The mean duration of arrhythmia conver-
sion was 19 min. Clearly, the drug was more effective than
placebo except at the lowest drug dose, where there was a
dose–response linearity, the response reaching a plateau at the
highest dose but one. Overall, 34% of patients converted to
sinus rhythm; a proarrhythmic reaction in the form of poly-
morphic ventricular tachycardia developed in 3.6% of patients
receiving ibutilide. There were no fatalities, and the proar-
rhythmia could be successfully treated with DC cardioversion,
without recurrence. It was noteworthy that the overall conver-
sion rates were 38% for AFL and 29% for AF.
The second of the two studies on the effects of repeated
doses of intravenous ibutilide in AF and AFL was recently
reported by Stambler et al. (7); 266 patients with sustained AF
(n 5 133) and AFL (n 5 133) 3 to 45 days in duration were
included in the study. They were randomized to receive up to
two 10-min infusions, separated by a 10-min interval, of
ibutilide (1.0 and 0.5 mg or 1.0 and 1.0 mg) or placebo. The
placebo conversion rate was 2%, and that for ibutilide was 47%
(p , 0.0001); the two ibutilide regimens restored sinus rhythm
in 44% of patients versus 49%, respectively. As noted in the
other study, efficacy was higher for AFL than for AF (63% vs.
31%, p , 0.0001). Fifteen (8.3%) of 180 patients who received
ibutilide developed polymorphic ventricular tachycardia dur-
ing or shortly after the infusion. Cardioversion was required in
3 patients (1.7%) and was nonsustained in 12 (6.7%). The drug
was effective in 63% of patients with AFL, and the incidence of
torsade de pointes was 12.5%. Again, there were no fatalities
or delayed occurrences of proarrhythmia.
What are the implications of the data summarized from
these three studies—one with dofetilide and the other two with
ibutilide in the acute conversion of AF and AFL to sinus
rhythm? Dofetilide and ibutilide are very similar drugs elec-
trophysiologically. Although both drugs prolong atrial and
ventricular repolarization, dofetilide blocks only one ionic
channel (rapid component of the delayed rectifier current [IKr]).
In contrast, it appears that ibutilide not only blocks IKr, but it
also enhances the inward sodium current during the plateau
phase of the action potential. Yet, both drugs appear to have
similar potencies for the termination of AF and AFL, and their
actions are associated with a defined incidence of proarrhyth-
mic reaction in the form of polymorphic ventricular tachycar-
dia. The clinically significant difference is that ibutilide is not
active orally and is unlikely to be evaluated for this indication,
whereas dofetilide is being developed for the prophylactic
maintenance of sinus rhythm after cardioversion of AF and
AFL. The observation that both ibutilide and dofetilide are
more effective in terminating AFL than AF is of much
electrophysiologic interest, as is the finding that class Ic drugs
do the very converse (8). The precise electrophysiologic basis
for such a difference is still not clear. An appealing explanation
might be that because ibutilide and dofetilide, like most IKr
blockers, exhibit the property of reverse-use dependency of
action on repolarization, they are likely to be more effective in
arrhythmias with slower atrial rates, such as AFL, rather than
AF. In contrast, the effects of class Ic drugs on the atrial
effective refractory period increase as the rate is increased (9).
Therapeutic implications. There is little doubt that pure
class III antiarrhythmic agents can predictably convert AF and
AFL to sinus rhythm in some patients. Is it clinically meaning-
ful and compelling enough to supersede conventional ap-
proaches with DC cardioversion? The data on ibutilide are
consistent but not compelling as to the overall percentage of
conversion, especially in the case of AF (i.e., ;30% of patients
with AF of relatively short duration). The overall conversion
rate might be even lower in patients with a greater chronicity of
the arrhythmia and those with more severe underlying disease.
If one were to adopt the routine use of standardized chemical
conversion of AF using these newer drugs, over two-thirds of
patients would receive the intravenous drugs without produc-
ing conversion and be subject to the risk of potential proar-
rhythmic reactions. At face value, the use of chemical conver-
sion may appear to have a larger role in the case of acute
treatment of AFL in which the rate of conversion is higher but
appears to be associated with a somewhat greater frequency of
proarrhythmic reactions. However, even here the data are
from patients with arrhythmia of relatively short duration, and
Abbreviations and Acronyms
AF 5 atrial fibrillation
AFL 5 atrial flutter
DC 5 direct current
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the success rate may be lower with more chronic forms of the
arrhythmia. Moreover, in AFL after initial rate control, there
is now an increasing tendency to undertake electrode catheter
ablation when applicable. This approach may reduce the
number of patients with AFL who may need chemical or
electrical conversion. However, as pointed out by Ellenbogen
et al. (6), there is no denying that there are patients who might
prefer chemical conversion to DC cardioversion, and undoubt-
edly there are clinical situations in which chemical conversion
might be clinically more expedient. Clearly, these situations
need further delineation with respect to risk- and cost-benefit
ratios. As emphasized recently by Roden (10), the relatively
high incidence of proarrhythmic reactions associated with
attempts at chemical conversion with class III agents is of
concern; the incidence might be higher as these drugs are used
in clinical settings that are less well controlled than those of the
investigative protocols. Thus, if these drugs are to be used (and
ibutilide is already approved in the United States) for the acute
conversion of AF or AFL preparatory to starting prophylactic
antifibrillatory therapy, other issues arise that remain to be
addressed. For example, does the occurrence of torsade de
pointes during or after acute conversion with a pure class III
agent predict the development of the same proarrhythmia
during prophylactic oral therapy with the same or similar QT
interval-prolonging drugs? Similarly, how soon after chemical
conversion by a class III compound might it be safe to initiate
oral therapy with another class III agent? These questions are
clearly of importance in the case of ibutilide. In the case of
dofetilide, is the conversion by intravenous drug predictive of
long-term stability of sinus rhythm on prophylactic therapy?
For the present, it appears to be premature to speculate as to
the extent to which chemical conversion will replace DC
cardioversion of AF and AFL. However, the newer data with
dofetilide and, in particular, ibutilide will undoubtedly provide
a fresh impetus to identify the safest and most effective agents
for conversion and the most appropriate clinical settings in
which to use DC cardioversion and those in which to resort to
pharmacologic conversion of AF and AFL.
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